Mªconcepción Romero Sánchez *

Autor invitado por SIIC

El trabajo analiza el efecto neto de un régimen con maraviroc y sus potenciales efectos inmunovirológicos

BIOMARCADORES RELACIONADOS CON LA PROGRESIÓN DE LA ENFERMEDAD POR VIH

Con la introducción de la terapia antirretroviral de gran actividad, han disminuido en forma notable la morbilidad y la mortalidad asociadas con el sida.

*Mªconcepción Romero Sánchez
describe para SIIC los aspectos relevantes de su trabajo
EFFECT OF MARAVIROC ON HIV DISEASE PROGRESSION-RELATED BIOMARKERS
Institución principal de la investigación
*Instituto de Biomedicina de Sevilla. Hospital Universitario Virgen del Rocío, Sevilla, España
Imprimir nota

Comprar este artículo
Otros artículos escogidos

Referencias bibliográficas
1. Asmuth DM, et al. CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 54:394-397, 2010.
2. Badley AD, et al. Dynamic correlation of apoptosis and immune activation during treatment of HIV infection. Cell Death Differ 6:420-432, 1999.
3. Baker JV, et al. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr 56:36-43, 2011.
4. Boulware DR, et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis 203:1637-1646, 2011.
5. Bucy RP, et al. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 103:1391-1398, 1999.
6. Cao W, et al. Premature aging of T cells is associated with faster HIV-1 disease progression. J Acquir Immune Defic Syndr 50:137-147, 2009.
7. Dorr P, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49:4721-4732, 2005.
8. Ferrando Martínez S, Ruiz Mateos E, Leal M. CD27 and CCR7 expression on naive T cells, are both necessary? Immunol Lett 127:157-158, 2010.
9. Franco JM, et al1999. Reduction of immune system activation in HIV-1-infected patients undergoing highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis 18:733-736, 1999.
10. Funderburg N, et al. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. PLoS One 5:e13188.doi:10.1371/journal.pone.0013188, 2010.
11. Genebat M, et al. Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients. J Antimicrob Chemother 64:845-849, 2009.
12. Giorgi JV, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 179:859-870, 1999.
13. Giorgi JV, et al. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. J Acquir Immune Defic Syndr 6:904-912, 1993.
14. Gutierrez C, et al. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. PLoS One 6:e27864. doi:10.1371/journal.pone.0027864, 2011.
15. Hazenberg MD, et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 95:249-255, 2000.
16. Kuller LH, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 5:e203.doi:10.1371/journal.pmed.0050203, 2008.
17. Liu Z, et al. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 16:83-92, 1997.
18. Palella FJ Jr, et al. Increased mortality among publicly insured participants in the HIV Outpatient Study despite HAART treatment. AIDS 25:1865-1876, 2011.
19. Palella FJ Jr, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338:853-860, 1998.
20. Pulido I, et al. T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity. J Infect 64:417-423, 2012.
21. Rossi R, et al. Downregulation of leukocyte migration after treatment with CCR5 antagonist maraviroc. J Acquir Immune Defic Syndr 54:e13-e14, 2010.
22. Ruiz Mateos E, et al. Virological response after short-term CCR5 antagonist exposure in HIV-infected patients: frequency of subjects with virological response and associated factors. Antimicrob Agents Chemother 55:4664-4669, 2011.
23. Saag M, et al. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis 199:1638-1647, 2009.
24. Sandler NG, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 203:780-790, 2011.
25. Wilkin TJ, Ribaudo HR, Tenorio AR, Gulick RM. The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients. HIV Clin Trials 11:351-358, 2010.

Otros artículos de Mªconcepción Romero Sánchez

Machmach K, Abad-Molina C, Romero-Sánchez MC, Abad MA, Ferrando-Martínez S, Genebat M, Pulido I, Viciana P, González-Escribano MF, Leal M, Ruiz-Mateos E; the HIV Controllers Consortium of the AIDS Spanish Network. IL28B single-nucleotide polymorphism rs12979860 is associated with spontaneous HIV control in white subjects. J Infect Dis 2012 [Epub ahead of print].
Cantisán S, Martín C, Romero-Sánchez MC, Ferrando-Martínez S, Martínez F, Rivero A, Torres A, Solana R, Torre-Cisneros J. Role of defective thymic function in onset of ganciclovir-resistant cytomegalovirus after cord blood transplantation. Clin Vaccine Immunol 19(12):1994-8, 2012.
Romero-Sánchez M, González-Serna A, Pacheco YM, Ferrando-Martínez S, Machmach K, García-García M, Álvarez-Ríos AI, Vidal F, Leal M, Ruiz-Mateos E. Different biological significance of sCD14 and LPS in HIV-infection: importance of the immunovirology stage and association with HIV-disease progression markers. J Infect 65(5):431-8, 2012.
Genebat M, Pulido I, Romero-Sánchez MC, González-Serna A, Ferrando-Martínez S, Machmach K, Pacheco YM, Muñoz-Fernández MÁ, Ruiz-Mateos E, Leal M. Patients on a combined antiretroviral therapy after maraviroc clinical test show no immunovirological impairment. Antiviral Res 95(3):207-11, 2012.
Gonzalez-Serna A, Romero-Sánchez MC, Ferrando-Martinez S, Genebat M, Vidal F, Muñoz-Fernández MÁ, Abad MA, Leal M, Ruiz-Mateos E. HIV-1 tropism evolution after short-term maraviroc monotherapy in HIV-1-infected patients. Antimicrob Agents Chemother 56(7):3981-3, 2012.
Pulido I, Machmach K, Romero-Sánchez MC, Genebat M, Mendez-Lagares G, Ruiz-Mateos E, Leal M. T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity. J Infect 64(4):417-23, 2012.
Ferrando-Martínez S, Romero-Sánchez MC, Solana R, Delgado J, de la Rosa R, Muñoz-Fernández MA, Ruiz-Mateos E, Leal M. Thymic function failure and C-reactive protein levels are independent predictors of all-cause mortality in healthy elderly humans. Age (Dordr). 35(1):251-9, 2013.
Ferrando-Martínez S, Ruiz-Mateos E, Romero-Sánchez MC, Muñoz-Fernández MÁ, Viciana P, Genebat M, Leal M. HIV infection-related premature immunosenescence: high rates of immune exhaustion after short time of infection. Curr HIV Res 9(5):289-94, 2011.
Ruiz-Mateos E, Machmach K, Romero-Sanchez MC, Ferrando-Martinez S, Viciana P, Del Val M, Muñoz-Fernandez MA, Genebat M, Leal M; Cohort of the Spanish AIDS Research Network. Hepatitis C virus replication in Caucasian HIV controllers. J Viral Hepat 18(7):e350-7, 2011.
Genebat M, Ruiz-Mateos E, Pulido I, González-Serna A, García-Pergañeda A, Méndez G, Romero-Sánchez MC, Ferrando-Martínez S, Leal M. Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice. Curr HIV Res 8(6):482-6, 2010.

Para comunicarse con Mªconcepción Romero Sánchez mencionar a SIIC como referencia:
mconcepcionrs@gmail.com

---

Acerca del trabajo completo

BIOMARCADORES RELACIONADOS CON LA PROGRESIÓN DE LA ENFERMEDAD POR VIH

Título original en castellano
EFECTO DE MARAVIROC EN BIOMARCADORES RELACIONADOS CON LA PROGRESION DE LA ENFERMEDAD VIH

Autores
Mªconcepción Romero Sánchez¹, Kawthar Machmach², Alejandro González Serna³, Miguel Genebat⁴, Ildefonso Pulido⁵, Manuel Leal Noval⁶, Ana Isabel Álvarez Ríos⁷, Sara Ferrando Martínez⁸, Ezequiel Ruiz Mateos⁹
1 Investigadora, Instituto de Biomedicina de Sevilla. Hospital Universitario Virgen del Rocío, Sevilla, España, Investigadora
2
3
4
5
6
7
8
9

Acceso a la fuente original
Antimicrobial Agents and Chemotherapy
http://aac.asm.org/

El artículo se relaciona estrictamente con las especialidades de siicsalud
El artículo se conecta secundariamente con las especialidades